Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Antibiotic Disincentives? Medicare Decisions Underscore Limits Of Add-On Payments

Executive Summary

CMS disappointed stakeholders looking for antibiotic payment incentives from Medicare with two recent decisions. One was to withhold new technology add-on payments from Dalvance and the other to allow existing NTAP benefits for Dificid to expire.

Advertisement

Related Content

Dalvance Approval Is Durata’s GAIN: First Test Of FDA’s Antibiotics Incentives
Optimer’s Dificid Gets Medicare Payment “Add-On” For Hospital Patients

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS056320

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel